Novo Nordisk incoming CEO Mike Doustdar speaks at call

Novo Nordisk incoming CEO Mike Doustdar speaks at call

Novo Nordisk's new CEO, Maziar Mike Doustdar, addressed investors and financial professionals during a recent call, providing insights into the company's strategic direction and market challenges. Doustdar, who took over from Lars Fruergaard Jorgensen on July 29, 2025, emphasized the importance of reviving Novo Nordisk's performance in the United States, the largest market for weight-loss drugs [1].

Doustdar acknowledged the challenges faced by the company, including the recent growth warning and the threat of U.S. President Donald Trump's tariffs and calls to lower drug prices [2]. He highlighted the need for swift and ambitious action to address these challenges and build on Novo Nordisk's strengths as a global leader in obesity and diabetes [3].

The new CEO also discussed the company's plans to merge the Research & Early Development and Development areas into a consolidated R&D unit, with Martin Holst Lange taking on the role of chief scientific officer. This move aims to quickly advance the innovation of new therapies and ensure the success of the early and late-stage pipelines, with a significant focus on diabetes and obesity [3].

Doustdar expressed confidence in Novo Nordisk's ability to navigate these challenges and continue delivering life-changing medicines to patients. He emphasized the company's strong science and the commitment of its people, stating that this has enabled Novo Nordisk to achieve great things in the past and will ensure continued success in the future.

References:
[1] Reuters. (2025, July 29). Obesity drugmaker Novo Nordisk picks Maziar Mike Doustdar as new CEO. Retrieved from https://www.reuters.com/sustainability/boards-policy-regulation/obesity-drugmaker-novo-nordisk-picks-maziar-mike-doustdar-new-ceo-2025-07-29/
[2] TradingView. (2025, July 29). Novo Nordisk named Maziar Mike Doustdar as new CEO. Retrieved from https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3TQ19M:0-obesity-drugmaker-novo-nordisk-picks-maziar-mike-doustdar-as-new-ceo/
[3] Novo Nordisk. (2025, July 29). Novo Nordisk announces new executive appointments. Retrieved from https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916408